Abstracts tagged "myeloperoxidase (MPO) and vasculitis"

Abstract Number: 1769 • 2017 ACR/ARHP Annual Meeting
Incidence, Predictors, and Outcome of Diffuse Alveolar Hemorrhage in Patients with MPO-ANCA Positive Microscopic Polyangiitis: A Multi-Center Retrospective Cohort Study
Takashi Kida, Shunya Kaneshita, Takuya Inoue, Amane Nakabayashi, Yuji Kukida, Kazuki Fujioka, Hidetake Nagahara, Makoto Wada, Takahiro Seno, Masataka Kohno and Yutaka Kawahito, Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Background/Purpose: In patients with microscopic polyangiitis (MPA), a variety of pulmonary lesions including diffuse alveolar hemorrhage (DAH), airways disease and interstitial lung disease (ILD) have…
Abstract Number: 1082 • 2015 ACR/ARHP Annual Meeting
ANCA-Negative and Myeloperoxidase-ANCA-Positive Patients with Granulomatosis with Polyangiitis: Clinical Manifestations and Risk of Relapse
Eli Miloslavsky¹, Na Lu², Sebastian Unizony³, Hyon K. Choi³, Peter A. Merkel⁴, Philip Seo⁵, Robert F. Spiera⁶, Carol A. Langford⁷, Gary S. Hoffman⁷, Cees Kallenberg⁸, E. William St.Clair⁹, Nadia Tchao¹⁰, Fernando Fervenza¹¹, Paul A. Monach¹², Ulrich Specks¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Johns Hopkins, Baltimore, MD, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology/Clin Immunol AA21, Univer Med Center Groningen, Groningen, Netherlands, ⁹Rheumatology and Immunology, Duke University, Durham, NC, ¹⁰ITN, San Francisco, CA, ¹¹Mayo Clinic, Rochester, MN, ¹²Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, ¹⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Recent studies in ANCA-associated vasculitis (AAV) have suggested that classification based on ANCA type (PR3 versus MPO) may represent a more clinically relevant division…
Abstract Number: 1773 • 2014 ACR/ARHP Annual Meeting
Otolaryngologic Lesions Are Not Rare and Closely Related with Pachymeningitis and Cranial Neuropathy in MPO-ANCA Associated Vasculitis
Takahiro Nunokawa¹, Naoto Yokogawa², Kota Shimada¹ and Shoji Sugii², ¹Department of Rheumatic diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ²Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
Background/Purpose: Recently several case reports of serous otitis media (SOM), hypertrophic pachymeningitis (HP) and cranial neuropathy (CN) have been reported in connection with MPO-ANCA associated…
Abstract Number: 734 • 2013 ACR/ARHP Annual Meeting
The Significance Of Anti-Myeloperoxidase and Anti-Proteinase 3 Antibodies In The Absence Of Anti-Neutrophil Cytoplasmic Antibody Immunofluorescence Positivity
Deepak A. Rao¹, Joseph F. Merola¹, William R. O'Brien¹, Kevin Wei¹, Samuel U. Takvorian², Paul F. Dellaripa³ and Peter H. Schur¹, ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Identification of serum anti-neutrophil cytoplasmic antibodies (ANCA) for the detection of ANCA-associated vasculitis (AAV) is often performed by screening with indirect immunofluorescence (IF), followed…
Abstract Number: 1536 • 2012 ACR/ARHP Annual Meeting
Clinical Features of Patients with Anti-Neutrophil Cytoplasmic Autoantibodies Targeting Native Myeloperoxidase Antigen
Yuji Yamanishi¹, Toshiko Ito-Ihara², Shigeto Kobayashi³, Peter Y. Shane⁴, Gary S. Firestein⁵, Hiroshi Hashimoto⁶ and Kazuo Suzuki⁷, ¹Division of Rheumatology, Hiroshima Rheumatology Clinic, Hiroshima, Japan, ²Department of Clinical Innovative Medicine, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, ³Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Div of Rheumatology, UCSD School of Medicine, La Jolla, CA, ⁶Juntendo Tokyo Koto Geriatric Center, Tokyo, Japan, ⁷National Institute of Infectious Diseases, Tokyo, Japan
Background/Purpose: ANCA is a useful diagnostic marker in systemic vasculitic disorders with small-vessel involvement, but depending on the particular test used the myeloperoxidase (MPO)-ANCA results…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].